The problem for BLT is the time line and cost profile to move this from mice to humans is HUGE, both in terms of number of years to get through the multiple FDA (or whatever country you choose) obstacles and the cost to do so.
Reality its an interesting and potentially great product but timeline and cost to fund the timeline mean it is best within a multinational's portfolio not a tiny AU companies, especially one with less than 1 year of funding.
- Forums
- ASX - By Stock
- BLT
- Ann: EFFICACY IN TRANSPLANT REJECTION
Ann: EFFICACY IN TRANSPLANT REJECTION , page-7
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online